{"id":"n-acetylcysteine-ppi-amoxicillin-clarithromycin","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Taste disturbance"},{"rate":"1-3","effect":"Allergic reactions (amoxicillin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"N-acetylcysteine acts as a mucolytic agent that breaks down biofilm and reduces mucus viscosity, improving antibiotic penetration. The PPI (proton pump inhibitor) reduces gastric acid, creating a more favorable pH environment for antibiotic activity and reducing acid-related damage. Amoxicillin and clarithromycin are bactericidal antibiotics that directly target and kill H. pylori cells.","oneSentence":"This combination therapy eradicates Helicobacter pylori infection by using antibiotics to kill the bacteria while N-acetylcysteine reduces mucus viscosity and a PPI suppresses gastric acid to optimize antibiotic efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:30.384Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication"}]},"trialDetails":[{"nctId":"NCT02249546","phase":"PHASE4","title":"Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-09","conditions":"Helicobacter Pylori Infection","enrollment":654}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"N-acetylcysteine + PPI-amoxicillin-clarithromycin","genericName":"N-acetylcysteine + PPI-amoxicillin-clarithromycin","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy eradicates Helicobacter pylori infection by using antibiotics to kill the bacteria while N-acetylcysteine reduces mucus viscosity and a PPI suppresses gastric acid to optimize antibiotic efficacy. Used for Helicobacter pylori infection eradication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}